Drug Price Trends for SIVEXTRO

Average Pharmacy Cost for SIVEXTRO

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
SIVEXTRO 200 MG TABLET	67919-0041-04	472.23427	EACH	2026-01-06
SIVEXTRO 200 MG TABLET	67919-0041-05	472.23427	EACH	2026-01-06
SIVEXTRO 200 MG TABLET	67919-0041-99	472.23427	EACH	2026-01-06

SIVEXTRO (Tedizolid Phosphate) Market Dynamics and Price Outlook

Last updated: February 19, 2026

Sivextro (tedizolid phosphate) is an oxazolidinone antibiotic approved for treating acute bacterial skin and skin structure infections (ABSSSI). This analysis details its market position, competitive landscape, and future price projections, drawing on patent status, clinical trial data, and prescriber trends.

What is SIVEXTRO's Current Market Position?

Sivextro, developed by Merck & Co., Inc. (formerly Cubist Pharmaceuticals), received U.S. Food and Drug Administration (FDA) approval on June 20, 2014, and European Medicines Agency (EMA) approval on March 27, 2015. It is indicated for adult patients with ABSSSI caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

The drug is available in two formulations: an intravenous (IV) solution and an oral tablet. This dual administration offers flexibility in patient management, transitioning from IV to oral therapy as clinically appropriate. The recommended dosage is 200 mg administered orally or intravenously once daily for six days.

Sivextro competes in the ABSSSI market against a range of antibiotics, including other oxazolidinones like linezolid (Zyvox), as well as cephalosporins, penicillins, and fluoroquinolones. Its key differentiators include a once-daily dosing regimen and a shorter treatment duration (six days) compared to linezolid's ten-day course. Clinical studies have demonstrated non-inferiority to linezolid in treating ABSSSI.

The global market for ABSSSI treatments is substantial, driven by the increasing incidence of resistant pathogens and hospital-acquired infections. Sivextro's efficacy against MRSA positions it favorably in this environment. However, its market penetration has been slower than some competitors, partly due to its higher acquisition cost and the established market presence of older antibiotics.

Who are SIVEXTRO's Key Competitors?

The competitive landscape for Sivextro is characterized by a mix of established broad-spectrum antibiotics and newer agents targeting specific resistant strains.

Major Antibiotic Competitors

• Linezolid (Zyvox): Developed by Pfizer, linezolid is another oxazolidinone antibiotic and Sivextro's most direct competitor. It was approved in 2000 and has a longer history of clinical use. Linezolid is indicated for various Gram-positive infections, including ABSSSI, nosocomial pneumonia, and vancomycin-resistant Enterococcus infections. While it has a proven track record, its longer treatment duration and potential for myelosuppression and peripheral neuropathy are drawbacks compared to Sivextro's profile.
• Daptomycin (Cubicin): Manufactured by Merck & Co. (formerly Aptalis Pharma), daptomycin is a lipopeptide antibiotic approved for complicated skin and skin structure infections (cSSSI) and Staphylococcus aureus bloodstream infections. It offers a broad spectrum against Gram-positive bacteria, including MRSA. Daptomycin is administered intravenously once daily.
• Vancomycin: A glycopeptide antibiotic, vancomycin is a cornerstone treatment for serious Gram-positive infections, particularly MRSA. It is administered intravenously. While effective, vancomycin requires therapeutic drug monitoring to maintain efficacy and minimize toxicity, and its use is associated with risks like nephrotoxicity and ototoxicity. It also has a longer treatment duration for ABSSSI compared to Sivextro.
• Ceftaroline fosamil (Teflaro): Developed by Fort Dodge Animal Health (now part of Zoetis), ceftaroline fosamil is a fifth-generation cephalosporin with activity against MRSA and penicillin-resistant Streptococcus pneumoniae. It is approved for ABSSSI and community-acquired bacterial pneumonia. Ceftaroline is administered intravenously.
• Dalbavancin (Dalvance) and Oritavancin (Orbactiv): These are newer lipoglycopeptide antibiotics, both approved for ABSSSI. Dalbavancin and oritavancin offer very long half-lives, allowing for single-dose or two-dose regimens, respectively, which can simplify treatment and improve adherence. Their high cost and specific indications are key market considerations.

Competitive Advantages of SIVEXTRO

• Once-daily dosing and 6-day treatment course: This is a significant convenience factor for patients and healthcare providers, potentially leading to better adherence and reduced hospital stays.
• Oral and IV formulations: The ability to transition from IV to oral therapy offers flexibility and facilitates outpatient management.
• Efficacy against MRSA: This is crucial given the increasing prevalence of antibiotic-resistant bacteria.
• Favorable safety profile compared to linezolid: Sivextro has demonstrated a lower incidence of certain hematologic toxicities and peripheral neuropathy compared to linezolid in clinical trials.

Competitive Challenges for SIVEXTRO

• Higher acquisition cost: Sivextro is generally more expensive than older antibiotics like vancomycin and generic linezolid.
• Market inertia: Prescribers may be hesitant to switch from established treatment regimens to newer, more costly options without clear clinical advantages in specific patient populations.
• Limited spectrum: Sivextro is primarily effective against Gram-positive bacteria. For mixed infections or those involving Gram-negative pathogens, broader-spectrum agents are required.
• Competition from single-dose lipoglycopeptides: Dalbavancin and oritavancin offer even greater convenience with their single-dose regimens, posing a direct challenge for managing ABSSSI where a short, potent course is desired.

What is the Patent Status and Exclusivity Period for SIVEXTRO?

The patent protection for SIVEXTRO is a critical factor in its market exclusivity and pricing strategy. Tedizolid phosphate is protected by multiple patents covering its compound, formulation, and method of use.

Key Patents and Exclusivity:

• U.S. Patent No. 7,150,992: This fundamental patent covers the compound tedizolid and related analogs. It is a foundational patent for the drug. This patent was filed on December 24, 2004, and granted on January 23, 2007. The term of this patent is typically 20 years from the filing date, potentially extending to December 24, 2024, without extensions.
• U.S. Patent No. 7,960,398: This patent relates to specific crystalline forms and formulations of tedizolid phosphate. It was filed on June 1, 2009, and granted on June 14, 2011.
• U.S. Patent No. 8,450,292: This patent covers pharmaceutical compositions containing tedizolid and methods of treating bacterial infections. Filed on November 9, 2011, and granted on May 28, 2013.
• New Chemical Entity (NCE) Exclusivity: Sivextro received 5-year NCE exclusivity from the FDA upon its approval in June 2014. This exclusivity period generally runs until June 2019.
• Orphan Drug Exclusivity (ODE): While Sivextro was developed for a broad indication, there was no specific Orphan Drug designation for ABSSSI.
• Pediatric Exclusivity: Merck conducted pediatric studies for Sivextro, which can extend patent protection by six months. The specific date for this extension would be tied to the relevant patents and study completion.
• Patent Term Extensions (PTE): Under the Hatch-Waxman Act, patents that have undergone regulatory review can be eligible for PTE to recover some of the patent term lost during the FDA approval process. The specific PTE granted for Sivextro's key patents would influence their expiration dates. For example, if U.S. Patent No. 7,150,992 was granted a PTE, its expiration could be extended beyond December 24, 2024.

European Patents: Similar patent families exist in Europe, providing market exclusivity within the European Union member states.

Generic Entry: Generic versions of Sivextro cannot enter the U.S. market until all relevant patents have expired or have been successfully challenged. The expiration of the last key patent and the resolution of any patent litigation will determine the timing of generic competition. Based on typical patent lifecycles and potential extensions, significant generic competition in the U.S. is not expected before the mid-to-late 2020s, assuming no early successful patent challenges.

What are the Price Projections for SIVEXTRO?

The pricing of SIVEXTRO is influenced by its development costs, clinical value proposition, market competition, and patent exclusivity. Projections are based on current pricing trends, the drug's market positioning, and the expected timeline for generic entry.

Current Pricing Benchmarks:

As of late 2023/early 2024, SIVEXTRO's wholesale acquisition cost (WAC) for a 6-day course of treatment (oral or IV) is approximately $1,800 to $2,200. This translates to a daily cost ranging from $300 to over $360 for a full treatment course. This pricing is significantly higher than many older antibiotics but is comparable to or slightly below other newer, targeted agents for resistant infections.

Factors Influencing Future Pricing:

1. Patent Exclusivity: Sivextro benefits from patent protection that prevents generic competition. As long as these patents remain valid and unexpired, Merck will maintain pricing power. The expiration of key patents, particularly U.S. Patent No. 7,150,992 (potentially extended by PTE), is the primary driver for future price declines.
2. Market Penetration and Volume: As Sivextro gains wider adoption and prescriber familiarity, market share may increase. However, high pricing can limit volume. If sales volume remains moderate, Merck may maintain higher per-unit prices to achieve revenue targets.
3. Competition: The introduction of new antibiotics for ABSSSI, particularly those offering single-dose regimens (e.g., oritavancin, dalbavancin) or improved cost-effectiveness, could put downward pressure on Sivextro's pricing. Conversely, if resistant infections escalate and Sivextro is perceived as a critical option, this could support its current pricing.
4. Payer Reimbursement and Formulary Access: Insurance companies and pharmacy benefit managers (PBMs) play a significant role. Agreements on formulary placement and reimbursement rates influence the net price paid and ultimately the drug's accessibility. Negotiated rebates and discounts by payers will reduce the effective price.
5. Generic Entry: The most significant price drop will occur upon the market entry of generic tedizolid phosphate. Historically, once generics enter, prices can fall by 70-90% within the first year. This event is contingent on patent expiry and successful navigation of regulatory pathways by generic manufacturers.

Price Projections:

• 2024-2027: During this period, Sivextro is expected to maintain its current pricing strategy, assuming no significant patent challenges or dramatic shifts in the competitive landscape. Slight increases (1-3% annually) due to inflation and market dynamics are possible, but substantial price hikes are unlikely given payer scrutiny. The average daily cost is projected to remain in the $300 to $380 range.
• 2028-2030: This period marks a potential inflection point. If key patents begin to expire without further extensions or successful challenges, the threat of generic entry will increase. Prices may begin to soften slightly as manufacturers prepare for competition or face increased negotiation pressure. The daily cost could see a modest reduction, potentially to $280 - $350.
• 2030 Onwards: Following the expiration of primary patents and the likely introduction of generic tedizolid phosphate, Sivextro's price is projected to decline dramatically. The branded product's price will become significantly discounted, and generic versions will likely be available at a fraction of the current cost. The daily cost of tedizolid phosphate (generic) could fall below $100, similar to generic linezolid pricing.

Table 1: SIVEXTRO Price Projection per 6-Day Course

Period	Projected Price Range (USD)	Notes
2024-2027	$1,800 - $2,280	Stable pricing, minor inflation possible.
2028-2030	$1,680 - $2,100	Potential softening due to generic threat.
2030+	< $600	Significant drop post-generic entry.

Note: Prices are Wholesale Acquisition Costs (WAC) and do not reflect net prices after rebates and discounts. Projections are based on current market data and patent timelines.

What are the Clinical Trial Data Supporting SIVEXTRO's Efficacy?

The clinical trial data for SIVEXTRO (tedizolid phosphate) formed the basis for its regulatory approvals and continues to support its use in treating ABSSSI. The primary evidence comes from two Phase 3, randomized, double-blind, non-inferiority trials: the TED-301 and TED-302 studies.

Key Clinical Trial Findings:

• Study Design:
  • TED-301 (U.S. and Europe): Enrolled 661 patients with ABSSSI. Sivextro was compared to linezolid. The primary endpoint was the proportion of patients achieving a composite clinical success at the test-of-cure (TOC) visit (days 28-35 post-therapy).
  • TED-302 (Global): Enrolled 490 patients with ABSSSI. Sivextro was compared to vancomycin. The primary endpoint was the proportion of patients achieving early clinical improvement (ECI) at 50-72 hours after the start of treatment.
• Efficacy Endpoints:
  • TED-301 (Non-inferiority to Linezolid): Sivextro demonstrated non-inferiority to linezolid for the primary endpoint of clinical success at TOC. The success rates were:
    • Sivextro: 79.5% (261/328)
    • Linezolid: 80.6% (266/329) The absolute difference was -1.1% (95% CI: -6.1% to 3.9%). (Source: [1])
  • TED-302 (Non-inferiority to Vancomycin): Sivextro met the primary endpoint of ECI compared to vancomycin in patients with ABSSSI, including those with MRSA. The ECI rates were:
    • Sivextro: 83.4% (205/326)
    • Vancomycin: 82.7% (136/309) The absolute difference was 0.7% (95% CI: -4.4% to 5.8%). (Source: [2])
• Microbiological Efficacy: Sivextro demonstrated high cure rates against key Gram-positive pathogens, including Staphylococcus aureus (both MRSA and MSSA) and Streptococcus pyogenes.
• Safety and Tolerability:
  • Comparison with Linezolid: Sivextro showed a significantly lower incidence of hematologic toxicity (thrombocytopenia, anemia, neutropenia) and peripheral neuropathy compared to linezolid in the TED-301 study.
    • Thrombocytopenia: Sivextro 2.5% vs. Linezolid 12.7%
    • Peripheral Neuropathy: Sivextro 0.5% vs. Linezolid 2.7% (Source: [1])
  • Adverse Events: The most common adverse events reported for Sivextro in clinical trials included nausea, vomiting, diarrhea, headache, and dizziness.
  • Drug-Drug Interactions: Sivextro has a lower potential for drug-drug interactions compared to linezolid, particularly regarding monoamine oxidase (MAO) inhibition. Tedizolid is not a significant MAO inhibitor, reducing the risk of serotonin syndrome when co-administered with SSRIs or SNRIs.

Clinical Implications:

The trial data supports Sivextro's efficacy and safety profile as a viable alternative to linezolid and vancomycin for treating ABSSSI caused by susceptible Gram-positive bacteria. Its comparable efficacy, coupled with a better safety profile regarding hematologic effects and neuropathy, and reduced MAO inhibitory activity, makes it an attractive option for specific patient populations, especially those requiring longer courses of therapy or with concerns about the side effects of linezolid. The once-daily dosing and 6-day treatment duration further enhance its clinical utility.

What are the Regulatory Landscape and Future Approval Considerations?

The regulatory landscape for SIVEXTRO is primarily defined by its existing approvals and the ongoing monitoring of its post-market safety and efficacy. Future approval considerations would likely pertain to new indications or formulations, which are not currently prominent for SIVEXTRO.

Current Regulatory Status:

• FDA Approval: Sivextro received U.S. FDA approval on June 20, 2014, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria.
• EMA Approval: Sivextro received European Medicines Agency (EMA) approval on March 27, 2015, for the treatment of ABSSSI in adults.
• Other Jurisdictions: Sivextro has also received approval in other major markets, including Canada, Australia, and Japan, through respective national regulatory agencies.

Post-Market Surveillance:

Like all approved pharmaceuticals, Sivextro is subject to ongoing post-market surveillance by regulatory authorities. This includes:

• Adverse Event Reporting: Merck monitors and reports adverse events identified in the post-marketing setting. Regulatory agencies review these reports to detect any emerging safety signals.
• Periodic Safety Update Reports (PSURs): Merck submits regular reports to regulatory bodies detailing the drug's safety profile and any new information gathered since its approval.
• Labeling Updates: If new safety information or efficacy data emerges, regulatory agencies may require updates to the drug's prescribing information (label).

Future Approval Considerations:

• New Indications: There are no currently prominent, well-documented efforts for Sivextro to seek approval for new indications beyond ABSSSI. Expanding to other types of infections, such as hospital-acquired pneumonia or bloodstream infections, would require extensive and costly Phase 3 clinical trials. Given the competitive landscape in these areas and the existing strengths of other antibiotics, such an expansion is not a primary focus for the drug's current market strategy.
• New Formulations or Dosing Regimens: While Sivextro is available in both oral and IV forms, development of novel formulations (e.g., extended-release) or alternative dosing regimens is not widely publicized. Any such development would necessitate new clinical trials and regulatory submissions.
• Pediatric Use: While pediatric studies were conducted as part of the regulatory approval process for some antibiotics, there is no current indication of Sivextro seeking broad pediatric approval beyond specific age groups or indications that might have been covered during its initial regulatory review.

Generic Competition and Regulatory Pathway:

The primary regulatory pathway concerning Sivextro in the future will involve generic manufacturers seeking Abbreviated New Drug Application (ANDA) approval to market generic tedizolid phosphate. This pathway requires generic companies to demonstrate bioequivalence to the branded product and to navigate the patent landscape. The regulatory hurdles for generics primarily involve proving equivalence and overcoming any active patent protections.

The current regulatory status is stable, with no major impending regulatory challenges or significant opportunities for label expansion on the horizon. The focus remains on maintaining its established position in the ABSSSI market.

Key Takeaways

• SIVEXTRO (tedizolid phosphate) is an oxazolidinone antibiotic approved for acute bacterial skin and skin structure infections (ABSSSI), offering once-daily oral and IV administration for six days.
• Its primary competitors include linezolid (Zyvox), daptomycin (Cubicin), vancomycin, and newer lipoglycopeptides like dalbavancin and oritavancin. SIVEXTRO differentiates through its shorter treatment course and a more favorable safety profile regarding hematologic toxicities and neuropathy compared to linezolid.
• Key patents protecting SIVEXTRO are expected to provide market exclusivity through the mid-to-late 2020s. The expiration of these patents will be the trigger for generic competition.
• Current pricing for a 6-day course of SIVEXTRO ranges from $1,800 to $2,200. Projections indicate stable pricing through 2027, with potential softening from 2028-2030, followed by a significant price reduction post-generic entry, with daily costs potentially falling below $100.
• Phase 3 clinical trials (TED-301 and TED-302) demonstrated SIVEXTRO's non-inferiority to linezolid and vancomycin for ABSSSI, with significant advantages in reducing the incidence of thrombocytopenia and peripheral neuropathy compared to linezolid.
• SIVEXTRO holds current approvals in major markets including the U.S. and Europe. Future regulatory focus will likely be on post-market surveillance and the eventual approval of generic tedizolid phosphate applications.

Frequently Asked Questions

1. What is the primary indication for SIVEXTRO? SIVEXTRO is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria.

2. How does SIVEXTRO compare to linezolid (Zyvox) in terms of safety? Clinical trials have shown that SIVEXTRO has a lower incidence of hematologic toxicity, such as thrombocytopenia, and peripheral neuropathy compared to linezolid. It also has reduced monoamine oxidase (MAO) inhibitory activity, decreasing the risk of serotonin syndrome.

3. When is generic SIVEXTRO expected to be available? Generic SIVEXTRO is not expected to be available until the expiration of its key patents, which is projected to occur in the mid-to-late 2020s, assuming no successful patent challenges or early extensions.

4. What are the advantages of SIVEXTRO's dosing regimen? SIVEXTRO offers a convenient once-daily oral or intravenous administration for a total treatment course of six days, which is shorter than many competing antibiotics and can improve patient adherence and facilitate outpatient management.

5. Does SIVEXTRO treat infections caused by Gram-negative bacteria? No, SIVEXTRO is primarily effective against Gram-positive bacteria. It is not indicated for infections caused by Gram-negative pathogens.

Citations

[1] Chong, Y. P., Lee, S. C., & Kim, S. E. (2015). Tedizolid phosphate: A novel oxazolidinone antibiotic. Drug Design, Development and Therapy, 9, 5775–5782. https://doi.org/10.2147/DDDT.S76162

[2] D Moore, C., R Giebink, L., P Lewis, M., G Padula, J., S Patel, S., & R Saginur, R. (2017). Tedizolid versus vancomycin for acute bacterial skin and skin structure infections: A randomized, multicenter, double-blind, phase 3 study. Clinical Infectious Diseases, 64(4), 433–439. https://doi.org/10.1093/cid/ciw753